The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Bisphosphonates: Preclinical Review
Open accessAbstract
Learning Objectives: After completing this course, the reader will be able to: Describe the mechanism of action of first-generation and nitrogen-containing bisphosphonates. Explain how the mechanism of action of the bisphosphonates might directly affect tumor growth. Discuss how the bisphosphonates might be incorporated into both the prevention and treatment of cancer. Access and take the CME test online and receive 1 hour of AMA PRA category 1 credit at CME.TheOncologist.com Bisphosphonates effectively inhibit osteoclast-mediated bone resorption and are integral in the treatment of benign and malignant bone diseases. The evolution of bisphosphonates over the past 30 years has led to the development of nitrogen-containing bisphosphonates (N-BPs), which have a mechanism of action different from that of the nonnitrogen-containing bisphosphonates. Studies conducted over the past decade have elucidated the mechanism of action and pharmacologic properties of the N-BPs. N-BPs exert their effects on osteoclasts and tumor cells by inhibiting a key enzyme in the mevalonate pathway, farnesyl diphosphate synthase, thus preventing protein prenylation and activation of intracellular signaling proteins such as Ras. Recent evidence suggests that N-BPs also induce production of a unique adenosine triphosphate analogue (Apppi) that can directly induce apoptosis. Our increased understanding of the pharmacologic effects of bisphosphonates is shedding light on the mechanisms by which they exert antitumor effects. As a result of their biochemical effects on protein prenylation, N-BPs induce caspase-dependent apoptosis, inhibit matrix metalloproteinase activity, and downregulate αvβ3 and αvβ5 integrins. In addition, zoledronic acid (Zometa®; Novartis Pharmaceuticals Corp.; East Hanover, NJ and Basel, Switzerland) exerts synergistic antitumor activity when combined with other anticancer agents. Zoledronic acid also inhibits tumor cell adhesion to the extracellular matrix and invasion through Matrigel™ and has antiangiogenic activity. A growing body of evidence from animal models demonstrates that zoledronic acid and other bisphosphonates can reduce skeletal tumor burden and prevent metastasis to bone. Further studies are needed to fully elucidate these biochemical mechanisms and to determine if the antitumor potential of bisphosphonates translates to the clinical setting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PROTEIN PRENYLATION: Molecular Mechanisms and Functional Consequences
Zhang, F. L., & Casey, P. J. (1996) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.65.070196.001325 · Cited by 1,743
Luckman, S. P., Hughes, D. E., Coxon, F. P., Russell, R. G. G., & Dr. Rogers, M. J. (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.4.581 · Cited by 1,176
Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo
Hughes, D. E., Wright, K. R., Uy, H. L., Sasaki, A., Yoneda, T., Roodman, D. G., Mundy, G. R., & Dr. Boyce, B. F. (1995) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650101008 · Cited by 1,040
Sato, M., Grasser, W., Endo, N., Akins, R., Simmons, H., Thompson, D. D., Golub, E., & Rodan, G. A. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115539 · Cited by 1,004
Cellular and molecular mechanisms of action of bisphosphonates
Rogers, M. J., Gordon, S., Benford, H. L., Coxon, F. P., Luckman, S. P., Monkkonen, J., & Frith, J. C. (2000) · Cancer · doi:10.1002/1097-0142(20000615)88:12+<2961::aid-cncr12>3.0.co;2-l · Cited by 977
Dunford, J. E., Thompson, K., Coxon, F. P., Luckman, S. P., Hahn, F. M., Poulter, C. D., Ebetino, F. H., & Rogers, M. J. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38786-5 · Cited by 900
Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid.
Wood, J., Bonjean, K., Ruetz, S., Bellahcène, A., Devy, L., Foidart, J. M., Castronovo, V., & Green, J. R. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.035295 · Cited by 854
Self-citationHuman T Cell Receptor γδ Cells Recognize Endogenous Mevalonate Metabolites in Tumor Cells
Gober, H.-J., Kistowska, M., Angman, L., Jenö, P., Mori, L., & De Libero, G. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021500 · Cited by 847
Fournier, P. G. J., Boissier, S., Filleur, S., Guglielmi, J., Cabon, F., Colombel, M. C., & Clézardin, P. (2002) · PubMed · Cited by 646
Boissier, S., Ferreras, M., Peyruchaud, O., Magnetto, S., Ebetino, F. H., Colombel, M. C., Delmas, P. D., Delaissé, J., & Clézardin, P. (2000) · PubMed · Cited by 573
Frith, J. C., Mönkkönen, J., Blackburn, G. M., Russell, R. G. G., & Rogers, M. J. (1997) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1997.12.9.1358 · Cited by 437
Bisphosphonates induce apoptosis in human breast cancer cell lines
Senaratne, S. G., Pirianov, G., Mansi, J. L., Arnett, T. R., & Langrish, V (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.1131 · Cited by 428
Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound
Green, J. R., Müller, K., & Jaeggi, K. A. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090521 · Cited by 415
Self-citationThe role of bisphosphonates in breast cancer: Development of bisphosphonates
Fleisch, H. (2001) · Breast Cancer Research · doi:10.1186/bcr414 · Cited by 407
Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti‐tumour activity
Shipman, C. M., Rogers, M. J., Apperley, J. F., Russell, R. G. G., & Croucher, P. I. (1997) · British Journal of Haematology · doi:10.1046/j.1365-2141.1997.2713086.x · Cited by 398
Bisphosphonate treatment inhibits the growth of prostate cancer cells.
Lee, M. V., Fong, E. D. M., Singer, F. R., & Guenette, R. S. (2001) · PubMed · Cited by 364
Santini, D., Vincenzi, B., Dicuonzo, G., Avvisati, G., Massacesi, C., Battistoni, F., Gavasci, M., Rocci, L., Tirindelli, M. C., Altomare, V., et al. (2003) · PubMed · Cited by 350
Jagdev, S. P., Coleman, R. E., Shipman, C. M., Rostami-H, A., & Croucher, P. I. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1727 · Cited by 346
Boissier, S., Magnetto, S., Frappart, L., Cuzin, B., Ebetino, F. H., Delmas, P. D., & Clézardin, P. (1997) · PubMed · Cited by 343
Lehenkari, P. P., Kellinsalmi, M., Näpänkangas, J. P., Ylitalo, K. V., Mönkkönen, J., Rogers, M. J., Azhayev, A., Väänänen, H. K., & Hassinen, I. E. (2002) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12222-5 · Cited by 333
Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro.
van der Pluijm, G., Vloedgraven, H., van Beek, E., van der Wee-Pals, L., Löwik, C., & Papapoulos, S. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118841 · Cited by 305
Yaccoby, S., Pearse, R. N., Johnson, C. L., Barlogie, B., Choi, Y., & Epstein, J. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03257.x · Cited by 305
Rogers, M. J., Watts, D. J., & Russell, R. G. G. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19971015)80:8+<1652::aid-cncr15>3.0.co;2-z · Cited by 285
The pharmacology of bisphosphonates and new insights into their mechanisms of action
Russell, R. G. G., Rogers, M. J., Frith, J. C., Luckman, S. P., Coxon, F. P., Benford, H. L., Croucher, P. I., Shipman, C., & Fleisch, H. A. (1999) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650140212 · Cited by 279
Bisphosphonates Induce Breast Cancer Cell Death In Vitro
Fromigue, O., Lagneaux, L., & Body, J.-J. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.11.2211 · Cited by 276
Luckman, S. P., Coxon, F. P., Ebetino, F. H., Russell, R. G. G., & Rogers, M. J. (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.11.1668 · Cited by 272
Croucher, P. I., De Raeve, H., Perry, M. J., Hijzen, A., Shipman, C. M., Lippitt, J., Green, J., Van Marck, E., Van Camp, B., & Vanderkerken, K. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.3.482 · Cited by 266
Self-citationIn vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates
Aparicio, A., Gardner, A., Tu, Y., Savage, A., Berenson, J., & Lichtenstein, A. (1998) · Leukemia · doi:10.1038/sj.leu.2400892 · Cited by 259
Hiraga, T., Williams, P. J., Mundy, G. R., & Yoneda, T. (2001) · PubMed · Cited by 256
Bisphosphonates: Pharmacology, Mechanisms of Action and Clinical Uses
Russell, R. G. G., Croucher, P. I., & Rogers, M. J. (1999) · Osteoporosis International · doi:10.1007/pl00004164 · Cited by 240
Molecular mechanisms of action of bisphosphonates
Rogers, M. J., Frith, J. C., Luckman, S. P., Coxon, F. P., Benford, H. L., M̈onkk̈onen, J., Auriola, S., Chilton, K. M., & Russell, R. G. G. (1999) · Bone · doi:10.1016/s8756-3282(99)00070-8 · Cited by 237
Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages.
Selander, K. S., Mönkkönen, J., Karhukorpi, E. K., Härkönen, P., Hannuniemi, R., & Väänänen, H. K. (1996) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09541-0 · Cited by 237
Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro
Benford, H. L., McGowan, N. W. A., Helfrich, M. H., Nuttall, M. E., & Rogers, M. J. (2001) · Bone · doi:10.1016/s8756-3282(01)00412-4 · Cited by 235
Corey, E., Brown, L. G., Quinn, J. E., Poot, M., Roudier, M. P., Higano, C. S., & Vessella, R. L. (2003) · PubMed · Cited by 227
Integrin αvβ3 expression confers on tumor cells a greater propensity to metastasize to bone
Pecheur, I., Peyruchaud, O., Serre, C., Guglielmi, J., Voland, C., Bourre, F., Margue, C., Cohen‐Solal, M., Buffet, A., Kieffer, N., et al. (2002) · The FASEB Journal · doi:10.1096/fj.01-0911fje · Cited by 223
Shipman, C. M., Croucher, P. I., Russell, R. G. G., Helfrich, M. H., & Rogers, M. J. (1998) · PubMed · Cited by 216
MMP Inhibition and Downregulation by Bisphosphonates
TERONEN, O., HEIKKILÄ, P., KONTTINEN, Y. T., LAITINEN, M., SALO, T., HANEMAAIJER, R., TERONEN, A., MAISI, P., & SORSA, T. (1999) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1999.tb07702.x · Cited by 200
Derenne, S., Amiot, M., Barillé, S., Collette, M., Robillard, N., Berthaud, P., Harousseau, J.-L., & Bataille, R. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.12.2048 · Cited by 195
Peyruchaud, O., Winding, B., Pécheur, I., Serre, C.-M., Delmas, P., & Clézardin, P. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.11.2027 · Cited by 173
Flanagan, A. M., & Chambers, T. J. (1991) · Calcified Tissue International · doi:10.1007/bf02555852 · Cited by 171
Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway.
Virtanen, S. S., Väänänen, H. K., Härkönen, P. L., & Lakkakorpi, P. T. (2002) · PubMed · Cited by 162
Mackie, P. S., Fisher, J. L., Zhou, H., & Choong, P. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2000.1679 · Cited by 157
Tassone, P., Tagliaferri, P., Viscomi, C., Palmieri, C., Caraglia, M., D’Alessandro, A. M., Galea, E., Goel, A., Abbruzzese, A., Boland, C. R., et al. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600986 · Cited by 156
In Vivo Effects of Bisphosphonates on the Osteoclast Mevalonate Pathway
Fisher, J., Rodan, G. A., & Reszka, A. A. (2000) · Endocrinology · doi:10.1210/endo.141.12.7921 · Cited by 156
Zoledronate Sensitizes Endothelial Cells to Tumor Necrosis Factor-induced Programmed Cell Death
Bezzi, M., Hasmim, M., Bieler, G., Dormond, O., & Rüegg, C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m308114200 · Cited by 139
Tassone, P., Forciniti, S., Galea, E., Morrone, G., Turco, M. C., Martinelli, V., Tagliaferri, P., & Venuta, S. (2000) · Leukemia · doi:10.1038/sj.leu.2401770 · Cited by 136
Oades, G. M., Senaratne, S. G., Clarke, I., Kirby, R. S., & Colston, K. W. (2003) · The Journal of Urology · doi:10.1097/01.ju.0000070685.34760.5f · Cited by 132
Senaratne, S. G., Mansi, J., & Colston, K. W. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600297 · Cited by 129
Kuroda, J., Kimura, S., Segawa, H., 裕, 小., Yoshikawa, T., Urasaki, Y., Ueda, T., Enjo, F., Tokuda, H., Ottmann, O. G., et al. (2003) · Blood · doi:10.1182/blood-2003-01-0305 · Cited by 122
Heikkilä, P., Teronen, O. P., Moilanen, M., Konttinen, Y. T., Hanemaaijer, R., Laitinen, M., Maisi, P. S., van der Pluijm, G., Bartlett, J. D., Salo, T. A., et al. (2002) · Anti-Cancer Drugs · doi:10.1097/00001813-200203000-00006 · Cited by 109
Alendronate Disturbs Vesicular Trafficking in Osteoclasts
Alakangas, A., Selander, K. S., Mulari, M. T. K., Halleen, J. M., Lehenkari, P. P., Mönkkönen, J., Salo, J., & nen, K. V. N. (2002) · Calcified Tissue International · doi:10.1007/s002230010047 · Cited by 104
Rogers, M. J., Ji, X., Russell, R. G. G., Blackburn, G. M., Williamson, M. P., Bayless, A. V., Ebetino, F. H., & Watts, D. J. (1994) · Biochemical Journal · doi:10.1042/bj3030303 · Cited by 102
Farnesyltransferase inhibitors: targeting the molecular basis of cancer
Oliff, A. I. (1999) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(99)00007-4 · Cited by 97
The Effect of the Bisphosphonate Ibandronate on Breast Cancer Metastasis to Visceral Organs
Michigami, T., Hiraga, T., Williams, P. J., Niewolna, M., Nishimura, R., Mundy, G. R., & Yoneda, T. (2002) · Breast Cancer Research and Treatment · doi:10.1023/a:1019905111666 · Cited by 93
Magnetto, S., Boissier, S., Delmas, P. D., & Clézardin, P. (1999) · International Journal of Cancer · Cited by 89
The antitumor potential of bisphosphonates
Clézardin, P. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.37420 · Cited by 84
The bisphosphonate pamidronate is a potent inhibitor of Ewing??s sarcoma cell growth in vitro
Sonnemann, J., Eckervogt, V., Truckenbrod, B., Boos, J., Winkelmann, W., & van Valen, F. (2003) · Anti-Cancer Drugs · doi:10.1097/00001813-200310000-00013 · Cited by 83
The bisphosphonate pamidronate is a potent inhibitor of human osteosarcoma cell growth in vitro
Sonnemann, J., Eckervogt, V., Truckenbrod, B., Boos, J., Winkelmann, W., & van Valen, F. (2001) · Anti-Cancer Drugs · doi:10.1097/00001813-200106000-00007 · Cited by 70
Metabolism of halogenated bisphosphonates by the cellular slime mould dictyostelium discoideum
Rogers, M. J., Russell, R. G. G., Blackburn, G. M., Williamson, M. P., & Watts, D. J. (1992) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(92)91574-a · Cited by 68
A newly developed bisphosphonate, YM529, is a potent apoptosis inducer of human myeloma cells
Takahashi, R., Shimazaki, C., Inaba, T., Okano, A., Hatsuse, M., Okamoto, A., Hirai, H., Ashihara, E., & Nakagawa, M. (2001) · Leukemia Research · doi:10.1016/s0145-2126(00)00087-4 · Cited by 61
Pelorgeas, S., Martin, J., & Satre, M. (1992) · Biochemical Pharmacology · doi:10.1016/0006-2952(92)90342-g · Cited by 59
Bisphosphonates in cancer therapy
Green, J. R. (2002) · Current Opinion in Oncology · doi:10.1097/00001622-200211000-00004 · Cited by 47
Self-citationCruz, J. C., Alsina, M., Craig, F. E., Yoneda, T., Anderson, J. L., Dallas, M., & Roodman, G. D. (2001) · Experimental Hematology · doi:10.1016/s0301-472x(01)00618-x · Cited by 37
Stronski, S. A., Bettschen-Camin, L., Wetterwald, A., Felix, R., Trechsel, U., & Fleisch, H. A. (1988) · Calcified Tissue International · doi:10.1007/bf02553751 · Cited by 31
Bisphosphonate Actions on Cancer
Yoneda, T., Hashimoto, N., & Hiraga, T. (2003) · Calcified Tissue International · doi:10.1007/s00223-002-0025-x · Cited by 30
Alvarez, E., Westmore, M. S., Galvin, R. J. S., Clapp, C. L., Considine, E. L., Smith, S. J., Keyes, K. A., Iversen, P. W., Delafuente, D. M., Sulaimon, S. S., et al. (2003) · PubMed · Cited by 29
Cited by
Systematic Review: Bisphosphonates and Osteonecrosis of the Jaws
Woo, S.-B., Hellstein, J. W., & Kalmar, J. R. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-10-200605160-00009 · Cited by 1,252
Bisphosphonates: The first 40years
Russell, R. G. G. (2011) · Bone · doi:10.1016/j.bone.2011.04.022 · Cited by 1,124
Morgan, G. J., Davies, F. E., Gregory, W. M., Cocks, K., Bell, S. E., Szubert, A. J., Navarro-Coy, N., Drayson, M. T., Owen, R. G., Feyler, S., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)62051-x · Cited by 575
Molecular Mechanisms of Action of Bisphosphonates: Current Status
Roelofs, A. J., Thompson, K., Gordon, S., & Rogers, M. J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0843 · Cited by 568
Bisphosphonates: Mode of Action and Pharmacology
Russell, R. G. G. (2007) · Pediatrics · doi:10.1542/peds.2006-2023h · Cited by 503
Metadata
- Authors
- Green, J. R.
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-09-01
- Volume
- 9
- Issue
- S4
- Pages
- 3-13
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- OpenAlex
- W2123171945
- Cited by
- 405
- References
- 66
- FWCI
- 11.02
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.